{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:46:59Z","timestamp":1758088019318,"version":"3.44.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,15]]},"DOI":"10.7759\/cureus.92409","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T04:35:25Z","timestamp":1757997325000},"source":"Crossref","is-referenced-by-count":0,"title":["Prophylactic Pegfilgrastim Versus On-Demand Filgrastim During Docetaxel and Cyclophosphamide Chemotherapy in Early-Stage Breast Cancer: A Retrospective Analysis"],"prefix":"10.7759","author":[{"given":"Hirona","family":"Banno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimihito","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanna","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Saitou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirai","family":"Ido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manami","family":"Gotou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andou","family":"Takahito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Kousaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.4.931","article-title":"Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23","volume":"19","author":"Fisher B","year":"2001","unstructured":"Fisher B, Anderson S, Tan-Chiu E, et al.. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol. 2001, 19:931-42. 10.1200\/JCO.2001.19.4.931","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.9.1483","article-title":"Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15","volume":"8","author":"Fisher B","year":"1990","unstructured":"Fisher B, Brown AM, Dimitrov NV, et al.. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 1990, 8:1483-96. 10.1200\/JCO.1990.8.9.1483","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.5391","article-title":"Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer","volume":"24","author":"Jones SE","year":"2006","unstructured":"Jones SE, Savin MA, Holmes FA, et al.. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006, 24:5381-7. 10.1200\/JCO.2006.06.5391","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.4028","article-title":"Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735","volume":"27","author":"Jones S","year":"2009","unstructured":"Jones S, Holmes FA, O'Shaughnessy J, et al.. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol. 2009, 27:1177-83. 10.1200\/JCO.2008.18.4028","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyp050","article-title":"Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients","volume":"39","author":"Takabatake D","year":"2009","unstructured":"Takabatake D, Taira N, Hara F, et al.. Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients. Jpn J Clin Oncol. 2009, 39:478-83. 10.1093\/jjco\/hyp050","journal-title":"Jpn J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2597-1","article-title":"Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel\/cyclophosphamide chemotherapy","volume":"23","author":"Kosaka Y","year":"2015","unstructured":"Kosaka Y, Rai Y, Masuda N, et al.. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel\/cyclophosphamide chemotherapy. Support Care Cancer. 2015, 23:1137-43. 10.1007\/s00520-014-2597-1","journal-title":"Support Care Cancer"},{"article-title":"TNM classification of malignant tumours, 8th edition","year":"2016","key":"ref7","unstructured":"TNM classification of malignant tumours, 8th edition. Brierley JD, Gospodarowicz MK, Wittekind C (ed). Wiley-Blackwell, New Jersey, USA; 2016."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0175","article-title":"Myeloid growth factors, version 2.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Crawford J","year":"2017","unstructured":"Crawford J, Becker PS, Armitage JO, et al.. Myeloid growth factors, version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017, 15:1520-41. 10.6004\/jnccn.2017.0175","journal-title":"J Natl Compr Canc Netw"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00028","article-title":"West German Study PlanB Trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer","volume":"37","author":"Nitz U","year":"2019","unstructured":"Nitz U, Gluz O, Clemens M, et al.. West German Study PlanB Trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer. J Clin Oncol. 2019, 37:799-808. 10.1200\/JCO.18.00028","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-016-4028-0","article-title":"Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review","volume":"161","author":"Fernandes R","year":"2017","unstructured":"Fernandes R, Mazzarello S, Stober C, et al.. Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review. Breast Cancer Res Treat. 2017, 161:1-10. 10.1007\/s10549-016-4028-0","journal-title":"Breast Cancer Res Treat"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-011-0035-5","article-title":"Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis","volume":"29","author":"Ngamphaiboon N","year":"2012","unstructured":"Ngamphaiboon N, O'Connor TL, Advani PP, Levine EG, Kossoff EB. Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis. Med Oncol. 2012, 29:1495-501. 10.1007\/s12032-011-0035-5","journal-title":"Med Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2165\/11586040-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of pegfilgrastim","volume":"50","author":"Yang BB","year":"2011","unstructured":"Yang BB, Kido A. Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet. 2011, 50:295-306. 10.2165\/11586040-000000000-00000","journal-title":"Clin Pharmacokinet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200304000-00002","article-title":"Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients","volume":"14","author":"Molineux G","year":"2003","unstructured":"Molineux G. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients. Anticancer Drugs. 2003, 14:259-64. 10.1097\/00001813-200304000-00002","journal-title":"Anticancer Drugs"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4646-1","article-title":"Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+\/PR+, HER2- vs. triple-negative","volume":"169","author":"Zhang L","year":"2018","unstructured":"Zhang L, Yu Q, Wu XC, et al.. Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+\/PR+, HER2- vs. triple-negative. Breast Cancer Res Treat. 2018, 169:175-87. 10.1007\/s10549-017-4646-1","journal-title":"Breast Cancer Res Treat"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-022-00272-9","article-title":"Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience","volume":"9","author":"Tsuboi S","year":"2023","unstructured":"Tsuboi S, Hayama T, Miura K, et al.. Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience. J Pharm Health Care Sci. 2023, 9:2. 10.1186\/s40780-022-00272-9","journal-title":"J Pharm Health Care Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6403-9","article-title":"Granulocyte-colony stimulating factor-associated aortitis in a woman with advanced breast cancer: a case report and review of the literature","volume":"19","author":"Hoshina H","year":"2019","unstructured":"Hoshina H, Takei H. Granulocyte-colony stimulating factor-associated aortitis in a woman with advanced breast cancer: a case report and review of the literature. BMC Cancer. 2019, 19:1217. 10.1186\/s12885-019-6403-9","journal-title":"BMC Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2019.02.013","article-title":"Granulocyte colony-stimulating factor-associated aortitis in the Japanese Adverse Drug Event Report database","volume":"119","author":"Oshima Y","year":"2019","unstructured":"Oshima Y, Takahashi S, Tani K, Tojo A. Granulocyte colony-stimulating factor-associated aortitis in the Japanese Adverse Drug Event Report database. Cytokine. 2019, 119:47-51. 10.1016\/j.cyto.2019.02.013","journal-title":"Cytokine"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3892\/mmr_00000066","article-title":"Effect of peg-filgrastim-supported dose-dense adjuvant chemotherapy on the peripheral blood leukocyte phenotype in breast cancer patients","volume":"2","author":"Collov\u00e0 E","year":"2009","unstructured":"Collov\u00e0 E, Rovati B, Grasso D, Bencardino K, Manzoni M, Danova M. Effect of peg-filgrastim-supported dose-dense adjuvant chemotherapy on the peripheral blood leukocyte phenotype in breast cancer patients. Mol Med Rep. 2009, 2:85-8. 10.3892\/mmr_00000066","journal-title":"Mol Med Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyy030","article-title":"Costs associated with febrile neutropenia in Japanese patients with primary breast cancer: post-hoc analysis of a randomized clinical trial","volume":"48","author":"Miyake O","year":"2018","unstructured":"Miyake O, Murata K, Tanaka S, Ishiguro H, Toi M, Tamura K, Kawakami K. Costs associated with febrile neutropenia in Japanese patients with primary breast cancer: post-hoc analysis of a randomized clinical trial. Jpn J Clin Oncol. 2018, 48:410-6. 10.1093\/jjco\/hyy030","journal-title":"Jpn J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2785","article-title":"Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer","volume":"5","author":"Pinato DJ","year":"2019","unstructured":"Pinato DJ, Howlett S, Ottaviani D, et al.. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 2019, 5:1774-8. 10.1001\/jamaoncol.2019.2785","journal-title":"JAMA Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13302","article-title":"Chemotherapy-driven dysbiosis in the intestinal microbiome","volume":"42","author":"Montassier E","year":"2015","unstructured":"Montassier E, Gastinne T, Vangay P, et al.. Chemotherapy-driven dysbiosis in the intestinal microbiome. Aliment Pharmacol Ther. 2015, 42:515-28. 10.1111\/apt.13302","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/297465-prophylactic-pegfilgrastim-versus-on-demand-filgrastim-during-docetaxel-and-cyclophosphamide-chemotherapy-in-early-stage-breast-cancer-a-retrospective-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T04:35:27Z","timestamp":1757997327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/297465-prophylactic-pegfilgrastim-versus-on-demand-filgrastim-during-docetaxel-and-cyclophosphamide-chemotherapy-in-early-stage-breast-cancer-a-retrospective-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.92409","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,9,15]]}}}